Dipanjan Karati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dipanjan Karati has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Swarupananda Mukherjee
Department of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata- Group of Institutions, Kolkata, India
8 shared publications Shreyasi Meur
6 shared publicationsSwarupananda Mukherjee
Department of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata-Group of Institutions, Kolkata, India
6 shared publicationsSantosh Prasad Chaudhary Kurmi
Department of Pharmacy, Universal College of Medical Sciences, Bhairahawa, Nepal
4 shared publicationsSiuli Sen
Techno India University
4 shared publicationsJanmajoy Banerjee
Department of Pharmaceutical Chemistry Gitanjali College of Pharmacy 731237 West Bengal India
3 shared publications
Latest Publications
- 28 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20, 1-15
From Light to Life: Potential Utility of Quantum Dots in Drug Delivery and Advanced Sciences
Driven by demand for new materials with intriguing features, the discipline of materials science and technology is rapidly advancing and now makes a significant contribution to research in nanoscale science. A material is classified based on the number of dimensions outside the nanoscale range in which particles are contained. Artificial nanocrystals with confinement in all three dimensions and nanometer-scale electron-transport capabilities are called quantum dots (QDs). Because of their distinct physical and optical properties, QDs have captivated scientists worldwide since their discovery in 1981. Their potential for use in a variety of optical-based biological applications makes them extremely desirable. QDs, which are nanocrystals smaller than 10 nm, possess unique optical, electrical, and chemical properties due to quantum confinement. QDs can be synthesised via colloidal, hydrothermal, and biomimetic methods. They have potential uses in biosensors, bioimaging, wastewater treatment, drug delivery, and quantum computing. QDs’ basic composition, size, surface functionalization, and dose are the primary variables affecting their biocompatibility and toxicity. Potential toxicity from oxidative stress and heavy metal release can be significantly reduced by using appropriate surface coating and encapsulation techniques. In 2011, the first human clinical trial using QD technology was approved by the USFDA. This innovative phase I exploratory trial used silica-based near-infrared QDs in a small number of patients with melanoma. This review provides a basic introduction to QDs, their preparation process, drug release mechanism, applications, challenges, toxicity concerns, and clinical trials. The role of artificial intelligence (AI), machine learning (ML), and deep learning in QD design, optimization, biocompatibility enhancement, and augmentation of therapeutic performance has been the focus, leading to a novel perspective.
- 28 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20, 1-15
From Light to Life: Potential Utility of Quantum Dots in Drug Delivery and Advanced Sciences
Driven by demand for new materials with intriguing features, the discipline of materials science and technology is rapidly advancing and now makes a significant contribution to research in nanoscale science. A material is classified based on the number of dimensions outside the nanoscale range in which particles are contained. Artificial nanocrystals with confinement in all three dimensions and nanometer-scale electron-transport capabilities are called quantum dots (QDs). Because of their distinct physical and optical properties, QDs have captivated scientists worldwide since their discovery in 1981. Their potential for use in a variety of optical-based biological applications makes them extremely desirable. QDs, which are nanocrystals smaller than 10 nm, possess unique optical, electrical, and chemical properties due to quantum confinement. QDs can be synthesised via colloidal, hydrothermal, and biomimetic methods. They have potential uses in biosensors, bioimaging, wastewater treatment, drug delivery, and quantum computing. QDs’ basic composition, size, surface functionalization, and dose are the primary variables affecting their biocompatibility and toxicity. Potential toxicity from oxidative stress and heavy metal release can be significantly reduced by using appropriate surface coating and encapsulation techniques. In 2011, the first human clinical trial using QD technology was approved by the USFDA. This innovative phase I exploratory trial used silica-based near-infrared QDs in a small number of patients with melanoma. This review provides a basic introduction to QDs, their preparation process, drug release mechanism, applications, challenges, toxicity concerns, and clinical trials. The role of artificial intelligence (AI), machine learning (ML), and deep learning in QD design, optimization, biocompatibility enhancement, and augmentation of therapeutic performance has been the focus, leading to a novel perspective.
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20, 1-20
Targeted Delivery of RNA-based Therapeutics by Lipid Nanoparticles
Lipid Nanoparticles (LNPs) have emerged as adaptable and effective delivery systems for RNA-based therapies, transforming contemporary medicine. This article covers the design, processes, and therapeutic potential of LNPs for RNA delivery. LNPs improve RNA encapsulation, stability, and targeted cellular delivery. Lipid nanoparticles protect RNA molecules from enzymatic degradation, enable endosomal escape, and allow cytoplasmic release for gene control or functional translation. Various RNA types are delivered using LNPs for specific therapeutic applications, such as mRNA for vaccines and protein replacement, siRNA for gene silencing in diverse genetic and oncological conditions, miRNA for gene expression modulation, and CRISPR/Cas9 components for targeted gene editing. LNP-mediated RNA therapies have demonstrated efficacy across a diverse array of diseases. The design and optimization of LNPs depend on several factors. In vivo studies and preclinical models have confirmed their safety and efficacy, leading to successful clinical trials and FDA-approved RNAbased therapies. However, challenges encompass immunogenicity, limited tissue selectivity, substantial production requirements, and longer safety duration. Recent advancements in ionizable lipid chemistry, microfluidic formulation, and targeted delivery techniques are broadening the therapeutic potential of LNPs, reinforcing their significance as essential carriers in the forthcoming era of precision RNA medicine.
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20, 1-20
Targeted Delivery of RNA-based Therapeutics by Lipid Nanoparticles
Lipid Nanoparticles (LNPs) have emerged as adaptable and effective delivery systems for RNA-based therapies, transforming contemporary medicine. This article covers the design, processes, and therapeutic potential of LNPs for RNA delivery. LNPs improve RNA encapsulation, stability, and targeted cellular delivery. Lipid nanoparticles protect RNA molecules from enzymatic degradation, enable endosomal escape, and allow cytoplasmic release for gene control or functional translation. Various RNA types are delivered using LNPs for specific therapeutic applications, such as mRNA for vaccines and protein replacement, siRNA for gene silencing in diverse genetic and oncological conditions, miRNA for gene expression modulation, and CRISPR/Cas9 components for targeted gene editing. LNP-mediated RNA therapies have demonstrated efficacy across a diverse array of diseases. The design and optimization of LNPs depend on several factors. In vivo studies and preclinical models have confirmed their safety and efficacy, leading to successful clinical trials and FDA-approved RNAbased therapies. However, challenges encompass immunogenicity, limited tissue selectivity, substantial production requirements, and longer safety duration. Recent advancements in ionizable lipid chemistry, microfluidic formulation, and targeted delivery techniques are broadening the therapeutic potential of LNPs, reinforcing their significance as essential carriers in the forthcoming era of precision RNA medicine.
- 15 August 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (8) , e71590
Luteolin as a Cancer Therapeutic: From Preclinical Evidence to Translational Potential
Cancer, a condition marked by the atypical development and multiplication of cells that may acquire aggressive properties, ranks among the foremost causes of mortality globally. Because of the problems with existing chemotherapy medications, cancer therapeutic research is being conducted to find substitute treatment approaches that are less harmful to healthy cells. The application of flavonoids has become a prominent area of interest in cancer therapy research. Luteolin, 3′,4′,5,7‐tetrahydroxyflavone, is a common flavonoid that may be found in many plants and medicinal herbs. Luteolin‐rich plants have been used to cure a variety of illnesses, including cancer, inflammatory conditions, and hypertension. Targeting cellular processes such as apoptosis, angiogenesis, migration, and cell cycle progression, luteolin's anticancer properties have been thoroughly studied in a variety of cancer types. It interacts with several proteins and signaling pathways to accomplish this. The development of contemporary luteolin research is outlined in this study, with an emphasis on preclinical data and translational prospects. This article reveals the chemistry, structure–activity relationship, and extraction techniques of luteolin. It explores pharmacological activities, mechanism of action, and advancements in nanoformulation strategies. Furthermore, it explains how luteolin's potential as a cancer treatment is demonstrated from preclinical proof to translational capability.
- 15 August 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (8) , e71590
Luteolin as a Cancer Therapeutic: From Preclinical Evidence to Translational Potential
Cancer, a condition marked by the atypical development and multiplication of cells that may acquire aggressive properties, ranks among the foremost causes of mortality globally. Because of the problems with existing chemotherapy medications, cancer therapeutic research is being conducted to find substitute treatment approaches that are less harmful to healthy cells. The application of flavonoids has become a prominent area of interest in cancer therapy research. Luteolin, 3′,4′,5,7‐tetrahydroxyflavone, is a common flavonoid that may be found in many plants and medicinal herbs. Luteolin‐rich plants have been used to cure a variety of illnesses, including cancer, inflammatory conditions, and hypertension. Targeting cellular processes such as apoptosis, angiogenesis, migration, and cell cycle progression, luteolin's anticancer properties have been thoroughly studied in a variety of cancer types. It interacts with several proteins and signaling pathways to accomplish this. The development of contemporary luteolin research is outlined in this study, with an emphasis on preclinical data and translational prospects. This article reveals the chemistry, structure–activity relationship, and extraction techniques of luteolin. It explores pharmacological activities, mechanism of action, and advancements in nanoformulation strategies. Furthermore, it explains how luteolin's potential as a cancer treatment is demonstrated from preclinical proof to translational capability.
- 16 April 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (4) , e70847
Taxifolin as a Promising Anticancer Agent: Molecular Mechanisms and Therapeutic Potentials
Taxifolin is emerging as a promising anticancer agent due to its diverse pharmacological profile, including anti‐inflammatory, antiproliferative, and antioxidant properties. Numerous in vitro and in vivo studies have demonstrated that taxifolin can modulate key signaling pathways associated with carcinogenesis, such as PI3K/Akt/mTOR, MAPK/ERK, and NF‐κB, which are frequently dysregulated in various cancers and crucial for angiogenesis, metastasis, cell survival, and proliferation. By targeting these molecular cascades, taxifolin can inhibit metastasis, suppress angiogenesis, induce apoptosis, and enhance the efficacy of conventional chemotherapy and radiotherapy while potentially reducing associated toxicity. Additionally, taxifolin's ability to chelate metal ions, scavenge reactive oxygen species, and modulate gene expression highlights its role as a chemopreventive agent. Its favorable pharmacokinetic profile and relatively low toxicity further support its suitability for long‐term use and combination therapy. However, despite its therapeutic potential, taxifolin faces challenges in clinical translation, such as low bioavailability and a lack of human clinical trials. Advancements in drug delivery strategies, including targeted delivery and nanoformulations, offer potential solutions to enhance the pharmacodynamics and efficacy of taxifolin. Overall, taxifolin's multifaceted anticancer effects and promising preclinical results warrant further investigation to harness its full potential as a novel therapeutic agent in the fight against cancer.
- 16 April 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (4) , e70847
Taxifolin as a Promising Anticancer Agent: Molecular Mechanisms and Therapeutic Potentials
Taxifolin is emerging as a promising anticancer agent due to its diverse pharmacological profile, including anti‐inflammatory, antiproliferative, and antioxidant properties. Numerous in vitro and in vivo studies have demonstrated that taxifolin can modulate key signaling pathways associated with carcinogenesis, such as PI3K/Akt/mTOR, MAPK/ERK, and NF‐κB, which are frequently dysregulated in various cancers and crucial for angiogenesis, metastasis, cell survival, and proliferation. By targeting these molecular cascades, taxifolin can inhibit metastasis, suppress angiogenesis, induce apoptosis, and enhance the efficacy of conventional chemotherapy and radiotherapy while potentially reducing associated toxicity. Additionally, taxifolin's ability to chelate metal ions, scavenge reactive oxygen species, and modulate gene expression highlights its role as a chemopreventive agent. Its favorable pharmacokinetic profile and relatively low toxicity further support its suitability for long‐term use and combination therapy. However, despite its therapeutic potential, taxifolin faces challenges in clinical translation, such as low bioavailability and a lack of human clinical trials. Advancements in drug delivery strategies, including targeted delivery and nanoformulations, offer potential solutions to enhance the pharmacodynamics and efficacy of taxifolin. Overall, taxifolin's multifaceted anticancer effects and promising preclinical results warrant further investigation to harness its full potential as a novel therapeutic agent in the fight against cancer.
- 13 April 2026
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 18 (10) , 1285-1293
Pyrroloquinoline quinone scaffolds: centrality in anticancer drug design
1. Cancer presently ranks as the second foremost cause of global mortality, after heart disease [1]. In 2022, there were more than 20 million newly diagnosed cancer cases and 9.7 million fatalities...
- 13 April 2026
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 18 (10) , 1285-1293
Pyrroloquinoline quinone scaffolds: centrality in anticancer drug design
1. Cancer presently ranks as the second foremost cause of global mortality, after heart disease [1]. In 2022, there were more than 20 million newly diagnosed cancer cases and 9.7 million fatalities...
- 6 April 2026
- Published by Wiley in Neurology and Clinical Neuroscience
Targeting Estrogen Receptors: A Molecular Approach to Combat Neurodegenerative Diseases
Background: A growing body of research points to disruptions in the estrogen as well as estrogen signaling route in a variety of mental illnesses. In addition to being essential for sexual maturation and reproduction, estrogens have a significant role in many other aspects of brain function, including memory, cognition, neurodevelopment, and neuroplasticity. Furthermore, new research on its neuroprotective and anti‐inflammatory properties has sparked interest in exploring its possible therapeutic application in mental illnesses. Objectives: The growing body of research on female hormone receptors and psychological conditions in preclinical and clinical investigations has been investigated in this review. Methods: The relevant information has been taken from literature search. Pubmed, Google Scholar, scopous search engines have been used for literature survey. Relevant studies (2010–2025) were selected using several keywords such as “neurological disorders”, “estrogen receptor”, “neuroinflammation” etc. The peer review articles were mainly focused on the role of ER receptor in neurodegenerative disorders. Non‐English, insufficient methodology describes articles were excluded. Relevant articles were selected on abstract, evaluation of their content. Results: In particular, we go over how estrogen receptors and estrogen signaling support neurological protective effects and cognition via modulating several brain systems, and we evaluate their disturbances and possible consequences in mental illnesses such as depression, schizophrenia, Parkinson's disease, and Alzheimer's disease. Conclusion: Additionally, this study examines potential future directions and issues in neurodegenerative diseases by evaluating therapeutic approaches utilizing estrogen and estrogen signaling.
- 6 April 2026
- Published by Wiley in Neurology and Clinical Neuroscience
Targeting Estrogen Receptors: A Molecular Approach to Combat Neurodegenerative Diseases
Background: A growing body of research points to disruptions in the estrogen as well as estrogen signaling route in a variety of mental illnesses. In addition to being essential for sexual maturation and reproduction, estrogens have a significant role in many other aspects of brain function, including memory, cognition, neurodevelopment, and neuroplasticity. Furthermore, new research on its neuroprotective and anti‐inflammatory properties has sparked interest in exploring its possible therapeutic application in mental illnesses. Objectives: The growing body of research on female hormone receptors and psychological conditions in preclinical and clinical investigations has been investigated in this review. Methods: The relevant information has been taken from literature search. Pubmed, Google Scholar, scopous search engines have been used for literature survey. Relevant studies (2010–2025) were selected using several keywords such as “neurological disorders”, “estrogen receptor”, “neuroinflammation” etc. The peer review articles were mainly focused on the role of ER receptor in neurodegenerative disorders. Non‐English, insufficient methodology describes articles were excluded. Relevant articles were selected on abstract, evaluation of their content. Results: In particular, we go over how estrogen receptors and estrogen signaling support neurological protective effects and cognition via modulating several brain systems, and we evaluate their disturbances and possible consequences in mental illnesses such as depression, schizophrenia, Parkinson's disease, and Alzheimer's disease. Conclusion: Additionally, this study examines potential future directions and issues in neurodegenerative diseases by evaluating therapeutic approaches utilizing estrogen and estrogen signaling.
- Open Access
- 15 February 2026
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 2
In silico identification of natural compounds from Couroupita guianensis as anticancer congeners targeting EGFR: Molecular docking and pharmacokinetic evaluations
- 15 February 2026
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 2
Open AccessIn silico identification of natural compounds from Couroupita guianensis as anticancer congeners targeting EGFR: Molecular docking and pharmacokinetic evaluations
- 7 January 2026
- Published by Elsevier in Pharmacological Research - Natural Products
- Vol. 10
Centella asiatica: An ethnobotanical treasure with promising anticancer properties
- 7 January 2026
- Published by Elsevier in Pharmacological Research - Natural Products
- Vol. 10
Centella asiatica: An ethnobotanical treasure with promising anticancer properties
- 20 November 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 115
Gadolinium based nanoplatform as drug delivery approach for targeted therapy
- 20 November 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 115
Gadolinium based nanoplatform as drug delivery approach for targeted therapy
- 6 November 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (11) , e70594
Curcumin Mediated Ferroptosis: An Auspicious Therapeutic Avenue in Cancer Treatment
Ferroptosis is newly recognized form of regular cell death which is associated with iron accumulation and lipid peroxidation in cells. This procedure leads to immense oxidative damage, inhibition of antioxidant defense, and a high generation of ROS. Ferroptosis progression is linked to mitochondrial dysfunction and p53 activation. In fact, excessive ROS generation after iron buildup leads to further mitochondrial lipid peroxidation. Curcumin, a naturally occurring polyphenolic chemical that comes from Curcuma longa , has a variety of pharmacological characteristics, such as anti‐inflammatory, anti‐neoplastic, and antioxidant actions. According to recent studies, curcumin and its derivatives can induce ferroptosis in cancerous cells, offering a novel means of halting tumor growth and overcoming drug resistance. Curcumin can induce ferroptosis in tumor cells via a number of regulatory mechanisms, such as those pertaining to the metabolism of iron, lipids, and amino acids. This might lead to the development of new therapeutic approaches for the treatment of cancer that is resistant to apoptosis. Ferroptosis is another way it affects anticancer immunotherapy. This study intends to demonstrate curcumin and its derivatives as strong inducers of ferroptosis and highlights their potential to transform cancer therapy paradigms by thoroughly reviewing the existing literature.
- 6 November 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (11) , e70594
Curcumin Mediated Ferroptosis: An Auspicious Therapeutic Avenue in Cancer Treatment
Ferroptosis is newly recognized form of regular cell death which is associated with iron accumulation and lipid peroxidation in cells. This procedure leads to immense oxidative damage, inhibition of antioxidant defense, and a high generation of ROS. Ferroptosis progression is linked to mitochondrial dysfunction and p53 activation. In fact, excessive ROS generation after iron buildup leads to further mitochondrial lipid peroxidation. Curcumin, a naturally occurring polyphenolic chemical that comes from Curcuma longa , has a variety of pharmacological characteristics, such as anti‐inflammatory, anti‐neoplastic, and antioxidant actions. According to recent studies, curcumin and its derivatives can induce ferroptosis in cancerous cells, offering a novel means of halting tumor growth and overcoming drug resistance. Curcumin can induce ferroptosis in tumor cells via a number of regulatory mechanisms, such as those pertaining to the metabolism of iron, lipids, and amino acids. This might lead to the development of new therapeutic approaches for the treatment of cancer that is resistant to apoptosis. Ferroptosis is another way it affects anticancer immunotherapy. This study intends to demonstrate curcumin and its derivatives as strong inducers of ferroptosis and highlights their potential to transform cancer therapy paradigms by thoroughly reviewing the existing literature.